Primary completion· ClinicalTrials.gov
Examination of How the Duration of Fasting and Temporary Stopping of GLP-1 Medications Affect the Amount of Food Left in the Stomach in Peop
Liraglutide History and Updates
222 events · 1999 – present
Synced daily from openFDA and ClinicalTrials.gov. Last sync: .
84
FDA Approvals
5
Label Revisions
1,885
Trial Milestones
10
Pivotal Publications
Source: openFDA, ClinicalTrials.gov via AACT, PubMed · Hipa.ai, 2026-06-12Download chart as PNG
This page tracks every FDA action, clinical trial milestone, and major publication for Liraglutide since 1999, drawn from openFDA, ClinicalTrials.gov, and PubMed.
All published updates (39)
2026
- FDA approvalLiraglutide: FDA Approves BIOCON PHARMA's Generic ANDA 215245· Mar 11, 2026
- FDA approvalLiraglutide ANDA 217234 Approved by FDA for ORBICULAR on Feb 24, 2026· Feb 24, 2026
- FDA approvalLiraglutide Generic Receives FDA Approval as ANDA 217063· Feb 24, 2026
- Results postedLiraglutide Shows Longer Time to HbA1c >=7% in Type 2 Diabetes GRADE Study· Feb 10, 2026
- Primary completionLiraglutide Phase 3 Study for Type 2 Diabetes Mellitus Reaches Primary…· Feb 7, 2026
- Label revisionLiraglutide Label Receives Boxed Warning for Thyroid C-Cell Tumors· Jan 30, 2026
- Label revisionLiraglutide Label Receives Boxed Warning for Thyroid C-Cell Tumors· Jan 30, 2026
- Results postedSemaglutide Achieves Greater Weight Loss vs. Other Obesity Medications· Jan 14, 2026
- FDA approvalLiraglutide: FDA Approves Generic Version by ORBICULAR on January 14, 2026· Jan 14, 2026
2025
- Primary completionLiraglutide + Metformin Combination Trial for PCOS, Obesity, Infertility…· Dec 31, 2025
- Primary completionInsulin Degludec Phase 3 Study for Type 2 Diabetes Reaches Primary Completion· Dec 31, 2025
- Primary completionLiraglutide Phase 3 Trial for Cirrhosis with Diabetes Reaches Primary Completion· Dec 30, 2025
- Label revisionLiraglutide Label Adds Boxed Warning for Thyroid C-Cell Tumors· Nov 13, 2025
- Primary completionLiraglutide/Insulin Degludec Phase 3 Trial Primary Completion Expected October…· Oct 31, 2025
- Label revisionLiraglutide Label Receives Boxed Warning for Thyroid C-Cell Tumors· Oct 16, 2025
- FDA approvalFDA Approves Liraglutide (ANDA 214568) for TEVA PHARMS.· Aug 27, 2025
- Results postedInsulin Icodec Shows Greater HbA1c Reduction in Type 2 Diabetes Trial· Aug 26, 2025
- FDA approvalFDA Approves Liraglutide Generic from Lupin on July 22, 2025· Jul 22, 2025
- Results postedLiraglutide Trial Shows Increased Epicardial Fat Thickness in Diabetes, CAD· Jul 8, 2025
- Results postedInsulin Efsitora Alfa Shows Similar Glycemic Control to Insulin Degludec in…· Jun 24, 2025
- Results postedLiraglutide-Related Trial: Insulin Icodec Less Effective in Type 1 Diabetes· Jun 12, 2025
- Results postedLiraglutide Alias Insulin Degludec Requires Higher Weekly Dose Than Efsitora…· Jun 3, 2025
- Results postedInsulin Efsitora Alfa Improves Time in Range for Type 2 Diabetes vs. Degludec· May 16, 2025
- Results postedLiraglutide Reduces Insulin Dose in Adolescents with Type 1 Diabetes· Apr 20, 2025
- FDA approvalLiraglutide (ANDA 218115) Gains FDA Approval as a Generic Drug· Apr 2, 2025
- Primary completionLiraglutide Phase 3 Trial for Obese Women with PCOS Completes Primary Data…· Mar 30, 2025
- Results postedLiraglutide Improves Peripheral Perfusion in Type 2 Diabetes with PAD· Mar 3, 2025
- Results postedLiraglutide Alias Insulin Degludec Compared to Icodec in T2D Trial· Feb 20, 2025
- Pivotal publicationLiraglutide Trial Published for Obesity in Children 6 to Under 12· Jan 1, 2025
2023
- Primary completionLiraglutide Phase 3 Study for Obesity in Children Reaches Primary Completion· Aug 1, 2023
2022
- Pivotal publicationLiraglutide: GRADE Study Publishes Glycemia Reduction Outcomes in Type 2…· Jan 1, 2022
- Pivotal publicationLiraglutide vs. Semaglutide for Body Weight in Overweight or Obese Adults· Jan 1, 2022
- Pivotal publicationLiraglutide: Type 2 Diabetes Glycemia Reduction, Microvascular, and CV…· Jan 1, 2022
2020
- Pivotal publicationLiraglutide Trial Results Published for Adolescent Obesity Weight Loss· Jan 1, 2020
2019
- Pivotal publicationLiraglutide Plus Metformin Shows Efficacy, Safety in Pediatric Type 2 Diabetes· Jan 1, 2019
- Pivotal publicationLiraglutide Efficacy and Safety Profile Compared in PIONEER 4 Type 2 Diabetes…· Jan 1, 2019
2018
- Pivotal publicationLiraglutide Reduces Type 2 Diabetes Risk and Manages Weight in Prediabetes· Jan 1, 2018
2016
- Pivotal publicationLiraglutide/Insulin Degludec Combination vs. Insulin Glargine for Type 2…· Jan 1, 2016
- Pivotal publicationLiraglutide Cardiovascular Outcomes in Type 2 Diabetes Published· Jan 1, 2016
Upcoming & expected milestones
Trial started· ClinicalTrials.gov
A Phase I Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Subcutaneous UBT38006 Injection in Healthy Adu
Primary completion· ClinicalTrials.gov
Liraglutide Treatment in Patients With Maturity-onset Diabetes of the Young (MODY)
Primary completion· ClinicalTrials.gov
A Study of LY3938577 in Healthy Participants and Participants With Type 1 Diabetes Mellitus (T1DM)
Primary completion· ClinicalTrials.gov
A Phase I Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Subcutaneous UBT38006 Injection in Healthy Adu
Primary completion· ClinicalTrials.gov
Liraglutide Effect in Atrial Fibrillation
Primary completion· ClinicalTrials.gov
Preoperative Use of Liraglutide Additionally to Common Dietological Measures as Opposed to Dietological Measures Alone
Primary completion· ClinicalTrials.gov
Evaluate the Efficacy and Safety of GZR101-80 Injection in Patients With Type 2 Diabetes
Primary completion· ClinicalTrials.gov
Liraglutide in Preventing Delirium in Diabetic Elderly After Cardiac Surgery
Primary completion· ClinicalTrials.gov
A Clinical Study to Evaluate the Pharmacokinetic and Pharmacodynamics Properties of of SHR-3167 in Subjects With Type 2 Diabetes
Primary completion· ClinicalTrials.gov
The Evira Study: Additional Support During Obesity Treatment
Primary completion· ClinicalTrials.gov
Evaluate the Efficacy and Safety of GZR33 Injection in Patients With Type 2 Diabetes
Primary completion· ClinicalTrials.gov
Effects of Exercise and GLP-1 Agonism on Muscle Microvascular Perfusion and Insulin Action in Adults With Metabolic Syndrome
Primary completion· ClinicalTrials.gov
Use of Liraglutide in Children Aged 6 to 12 Years With Severe Obesity
Primary completion· ClinicalTrials.gov
Study of Liraglutide (A Weight Loss Drug) in High Risk Obese Participants With Cognitive and Memory Issues
Primary completion· ClinicalTrials.gov
Saxenda: Underlying Mechanisms and Clinical Outcomes
Primary completion· ClinicalTrials.gov
Regimen Transition After Short-Term Intensive Insulin Therapy in Type 2 Diabetes
Primary completion· ClinicalTrials.gov
RWS of of Liraglutide Alone and in Combination With Orlistat for Weight Loss in Overweight/Obese Patients.
Primary completion· ClinicalTrials.gov
Efficacy and Safety of the Met+SGLT-2i+GLP-1RA in Patients With Type 2 Diabetes With Poor Glycemic Control
Primary completion· ClinicalTrials.gov
Effects of GH and Lirglutide on AgRP
Primary completion· ClinicalTrials.gov
The Effect of Glycemic Control and of GLP-1 Receptor Agonism on Islet GLP-1 in People With Type 1 and Type 2 Diabetes
Primary completion· ClinicalTrials.gov
Liraglutide Treatment in Obese Infertile PCOS Women
Past events
2026
Trial registered· ClinicalTrials.gov
A Phase I Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Subcutaneous UBT38006 Injection in Healthy Adu
Trial registered· ClinicalTrials.gov
Use of Liraglutide in Children Aged 6 to 12 Years With Severe Obesity
Trial started· ClinicalTrials.gov
RWS of of Liraglutide Alone and in Combination With Orlistat for Weight Loss in Overweight/Obese Patients.
Recall· FDA
Liraglutide Injection, 18 mg/3 mL (6 mg/mL), Rx only, Manufactured for: Lupin Pharmaceuticals, Inc., Naples, FL 34108, Manufactured by: Lupin Limited, Nagpur 441108, INDIA, a) 2 Pens- NDC 70748-346-02; b) 3 Pens - NDC 70748-346-03.
Trial registered· ClinicalTrials.gov
Evaluate the Efficacy and Safety of GZR33 Injection in Patients With Type 2 Diabetes
Trial started· ClinicalTrials.gov
Evaluate the Efficacy and Safety of GZR101-80 Injection in Patients With Type 2 Diabetes
Trial started· ClinicalTrials.gov
Evaluate the Efficacy and Safety of GZR33 Injection in Patients With Type 2 Diabetes
Trial started· ClinicalTrials.gov
Regimen Transition After Short-Term Intensive Insulin Therapy in Type 2 Diabetes
FDA approval· FDA
Sponsor: BIOCON PHARMA.
Primary completion· ClinicalTrials.gov
A Research Study of a New Medicine NNC0363-1063 in Healthy Participants and Participants With Type 1 Diabetes
Primary completion· ClinicalTrials.gov
A Study Comparing SHR-3167 and Insulin Degludec in Type 2 Diabetic Subjects Treated With Basal Insulin With or Without Oral Antidiabetic Dru
FDA approval (supplemental)· FDA
Sponsor: NOVO. Class: Labeling.
FDA approval· FDA
Sponsor: ORBICULAR.
FDA approval· FDA
Sponsor: BIOCON PHARMA.
Trial started· ClinicalTrials.gov
The Evira Study: Additional Support During Obesity Treatment
Results posted· ClinicalTrials.gov
A Comparative Effectiveness Study of Major Glycemia-lowering Medications for Treatment of Type 2 Diabetes
Primary completion· ClinicalTrials.gov
A Phase III Clinical Study to Assess the Efficacy and Safety of GZR4 in Subjects With Type 2 Diabetes Mellitus Treated With Basal Insulin
Trial registered· ClinicalTrials.gov
Evaluate the Efficacy and Safety of GZR101-80 Injection in Patients With Type 2 Diabetes
Label revision· FDA
WARNING: RISK OF THYROID C-CELL TUMORS • Liraglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures in both genders of rats and mice. It is unknown whether liraglutide causes th
Label revision· FDA
WARNING: RISK OF THYROID C-CELL TUMORS Liraglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures in both genders of rats and mice. It is unknown whether liraglutide causes thyr
Primary completion· ClinicalTrials.gov
Anti-obesity Pharmacotherapy and Inflammation
Trial registered· ClinicalTrials.gov
Research on Timing of Liraglutide Therapy in Patients With Obesity After Metabolic Surgery
Results posted· ClinicalTrials.gov
A Research Study Comparing Wegovy to Other Weight Management Drugs in People Living With Obesity in America
FDA approval· FDA
Sponsor: ORBICULAR.
2025
Primary completion· ClinicalTrials.gov
Liraglutide and Metformin Combination on Weight Loss, Metabolic - Endocrine Parameters and Pregnancy Rate in Women With PCOS, Obesity and In
Primary completion· ClinicalTrials.gov
LIGHT-MCI Trial: GLP-1 Agonist, SGLT2 Inhibitor, and DPP-4 Inhibitor for MCI Remission in Type 2 Diabetes
Primary completion· ClinicalTrials.gov
A Clinical Study of Insulin Degludec Injection in Subjects With Type 2 Diabetes
Primary completion· ClinicalTrials.gov
Safety, Tolerability and Preliminary Efficacy of Sublingual Liraglutide in Patients With Type 2 Diabetes Mellitus
Primary completion· ClinicalTrials.gov
Research on Optimal Strategy of Hypoglycemic Therapy for Cirrhosis With Diabetes
Trial registered· ClinicalTrials.gov
RWS of of Liraglutide Alone and in Combination With Orlistat for Weight Loss in Overweight/Obese Patients.
Primary completion· ClinicalTrials.gov
Liraglutide Plus Megestrol Acetate in Endometrial Atypical Hyperplasia
Trial registered· ClinicalTrials.gov
Efficacy and Safety of the Met+SGLT-2i+GLP-1RA in Patients With Type 2 Diabetes With Poor Glycemic Control
Results posted· ClinicalTrials.gov
Comparison of Type 2 Diabetes Pharmacotherapy Regimens
Label revision· FDA
WARNING: RISK OF THYROID C-CELL TUMORS WARNING: RISK OF THYROID C-CELL TUMORS Liraglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures in both genders of rats and mice. It is
Trial registered· ClinicalTrials.gov
Examination of How the Duration of Fasting and Temporary Stopping of GLP-1 Medications Affect the Amount of Food Left in the Stomach in Peop
Trial started· ClinicalTrials.gov
Examination of How the Duration of Fasting and Temporary Stopping of GLP-1 Medications Affect the Amount of Food Left in the Stomach in Peop
Primary completion· ClinicalTrials.gov
A Trial Investigating the Efficacy and Safety of Insulin Degludec/Liraglutide Injection in Subjects With Type 2 Diabetes
Label revision· FDA
WARNING: RISK OF THYROID C-CELL TUMORS Liraglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures in both genders of rats and mice. It is unknown whether liraglutide injection c
FDA approval (supplemental)· FDA
Sponsor: NANJING KING FRIEND. Class: Labeling.
FDA approval (supplemental)· FDA
Sponsor: NOVO NORDISK INC. Class: Labeling.
FDA approval (supplemental)· FDA
Sponsor: NOVO. Class: Labeling.
FDA approval (supplemental)· FDA
Sponsor: NOVO. Class: Labeling.
Trial started· ClinicalTrials.gov
The Effect of Glycemic Control and of GLP-1 Receptor Agonism on Islet GLP-1 in People With Type 1 and Type 2 Diabetes
Trial registered· ClinicalTrials.gov
Regimen Transition After Short-Term Intensive Insulin Therapy in Type 2 Diabetes
FDA approval· FDA
Sponsor: TEVA PHARMS.
Results posted· ClinicalTrials.gov
A Research Study to Compare a New Weekly Insulin, Insulin Icodec Used With DoseGuide App, and Daily Insulins in People With Type 2 Diabetes
Primary completion· ClinicalTrials.gov
Safety and Efficacy of Insulin Degludec/Insulin Aspart in Patients With T2DM
Trial started· ClinicalTrials.gov
A Clinical Study to Evaluate the Pharmacokinetic and Pharmacodynamics Properties of of SHR-3167 in Subjects With Type 2 Diabetes
FDA approval· FDA
Sponsor: LUPIN.
Primary completion· ClinicalTrials.gov
Phase 1 Study Assessing the Pharmacokinetics of NEX-22A in Subjects With T2D
Trial started· ClinicalTrials.gov
A Study Comparing SHR-3167 and Insulin Degludec in Type 2 Diabetic Subjects Treated With Basal Insulin With or Without Oral Antidiabetic Dru
Results posted· ClinicalTrials.gov
Liraglutide Effects on Epicardial Fat Inflammatory Genes
Primary completion· ClinicalTrials.gov
Outcome of Overweight AF Patients Following Ablation With a Potential Weight Loss Medication ( GOAL-AF )
Primary completion· ClinicalTrials.gov
Safety and Efficacy of Umbilical Cord Blood Regulatory T Cells Plus Liraglutide on Autoimmune Diabetes
Primary completion· ClinicalTrials.gov
Effect of Exercise and/or Liraglutide on Vascular Dysfunction and Insulin Sensitivity in Type 2 Diabetes ( ZQL007)
Results posted· ClinicalTrials.gov
A Study of Insulin Efsitora Alfa (LY3209590) Compared With Insulin Degludec in Participants With Type 1 Diabetes Treated With Multiple Daily
Trial registered· ClinicalTrials.gov
A Clinical Study to Evaluate the Pharmacokinetic and Pharmacodynamics Properties of of SHR-3167 in Subjects With Type 2 Diabetes
Trial registered· ClinicalTrials.gov
Liraglutide Treatment in Patients With Maturity-onset Diabetes of the Young (MODY)
Results posted· ClinicalTrials.gov
A Research Study to Compare a New Weekly Insulin, Insulin Icodec, and an Available Daily Insulin, Insulin Degludec, Both in Combination With
Trial registered· ClinicalTrials.gov
A Study Comparing SHR-3167 and Insulin Degludec in Type 2 Diabetic Subjects Treated With Basal Insulin With or Without Oral Antidiabetic Dru
Results posted· ClinicalTrials.gov
A Study of Insulin Efsitora Alfa (LY3209590) Compared With Insulin Degludec in Participants With Type 2 Diabetes Currently Treated With Basa
Primary completion· ClinicalTrials.gov
Research on Timing of Liraglutide Therapy in Patients With Obesity After Metabolic Surgery
Primary completion· ClinicalTrials.gov
LIROH - Liraglutide for Obesity in HIV
FDA approval (supplemental)· FDA
Sponsor: NOVO. Class: Labeling.
FDA approval (supplemental)· FDA
Sponsor: NOVO. Class: Labeling.
FDA approval (supplemental)· FDA
Sponsor: NOVO NORDISK INC. Class: Labeling.
Trial started· ClinicalTrials.gov
Liraglutide Treatment in Obese Infertile PCOS Women
Results posted· ClinicalTrials.gov
A Study of Insulin Efsitora Alfa (LY3209590) Compared to Degludec in Adults With Type 2 Diabetes Who Are Starting Basal Insulin for the Firs
Trial registered· ClinicalTrials.gov
The Effect of Glycemic Control and of GLP-1 Receptor Agonism on Islet GLP-1 in People With Type 1 and Type 2 Diabetes
Trial started· ClinicalTrials.gov
Liraglutide Treatment in Patients With Maturity-onset Diabetes of the Young (MODY)
Trial started· ClinicalTrials.gov
Preoperative Use of Liraglutide Additionally to Common Dietological Measures as Opposed to Dietological Measures Alone
Results posted· ClinicalTrials.gov
Liraglutide in Adolescents With Type 1 Diabetes
FDA approval· FDA
Sponsor: NANJING KING FRIEND.
Primary completion· ClinicalTrials.gov
Effect of Liraglutide in Obese Women With Polycystic Ovary Syndrome
Trial started· ClinicalTrials.gov
Efficacy and Safety of the Met+SGLT-2i+GLP-1RA in Patients With Type 2 Diabetes With Poor Glycemic Control
Primary completion· ClinicalTrials.gov
A Research Study in Saudi Arabia to Understand How the Dose Check App Used With Tresiba Treatment Helps to Control Blood Sugar Level
Primary completion· ClinicalTrials.gov
A Study to Test How a New Long-acting Insulin Works in the Body of Patients With Type 2 Diabetes During Exercise and Prolonged Fasting
Trial registered· ClinicalTrials.gov
Preoperative Use of Liraglutide Additionally to Common Dietological Measures as Opposed to Dietological Measures Alone
Results posted· ClinicalTrials.gov
Liraglutide and Peripheral Artery Disease
Primary completion· ClinicalTrials.gov
Effects of GLP-1RA on Body Weight, Metabolism and Fat Distribution in Overweight/Obese Patients With Type 2 Diabetes Mellitus
Trial registered· ClinicalTrials.gov
The Evira Study: Additional Support During Obesity Treatment
Results posted· ClinicalTrials.gov
A Research Study to Compare Two Types of Insulin, a New Weekly Insulin, Insulin Icodec and an Available Daily Insulin, Insulin Degludec, in
Trial started· ClinicalTrials.gov
A Phase III Clinical Study to Assess the Efficacy and Safety of GZR4 in Subjects With Type 2 Diabetes Mellitus Treated With Basal Insulin
FDA approval (supplemental)· FDA
Sponsor: NOVO NORDISK INC. Class: Labeling.
Trial registered· ClinicalTrials.gov
Investigation of the Relationship Between Peripheral and Central Metabolic Changes Induced by GLP-1 Agonists
Label revision· FDA
WARNING: RISK OF THYROID C-CELL TUMORS • Liraglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures in both genders of rats and mice. It is unknown whether liraglutide causes th
Primary completion· ClinicalTrials.gov
Liraglutide-bolus vs Glargine-bolus Therapy in Overweight/Obese Type 2 Diabetes Patients (LiraGooD)
Primary completion· ClinicalTrials.gov
Study to Evaluate the Safety and Effectiveness of Saxenda® for Weight Management in Routine Clinical Practice in Taiwan.
Trial registered· ClinicalTrials.gov
A Phase III Clinical Study to Assess the Efficacy and Safety of GZR4 in Subjects With Type 2 Diabetes Mellitus Treated With Basal Insulin
Primary completion· ClinicalTrials.gov
POSE2.0 With GLP-1 Agonist for Obesity Management
Pivotal publication· PubMed
SCALE KIDS: Research Study to Look at How Well a New Medicine is at Lowering Weight in Children With Obesity
2024
Primary completion· ClinicalTrials.gov
Comparison of Type 2 Diabetes Pharmacotherapy Regimens
FDA approval· FDA
Sponsor: HIKMA.
Trial registered· ClinicalTrials.gov
Liraglutide Treatment in Obese Infertile PCOS Women
Primary completion· ClinicalTrials.gov
Regulatory Post Marketing Surveillance (rPMS) Study of Xultophy® (Insulin Degludec/Liraglutide) to Evaluate Safety and Effectiveness in Pati
Primary completion· ClinicalTrials.gov
Investigation of the Relationship Between Peripheral and Central Metabolic Changes Induced by GLP-1 Agonists
Results posted· ClinicalTrials.gov
A Research Study to Compare Two Types of Insulin, a New Insulin, Insulin Icodec and an Available Insulin, Insulin Degludec, in People With T
Primary completion· ClinicalTrials.gov
A Research Study Comparing Wegovy to Other Weight Management Drugs in People Living With Obesity in America
Results posted· ClinicalTrials.gov
Liraglutide (Saxenda(R)) in Adolescents With Obesity After Sleeve Gastrectomy
Trial started· ClinicalTrials.gov
Liraglutide in Preventing Delirium in Diabetic Elderly After Cardiac Surgery
Trial registered· ClinicalTrials.gov
A Research Study of a New Medicine NNC0363-1063 in Healthy Participants and Participants With Type 1 Diabetes
Results posted· ClinicalTrials.gov
A Study to Investigate the Effect of MEDI0382 on Hepatic Glycogen Metabolism in Overweight and Obese Subjects With Type 2 Diabetes Mellitus.
Trial started· ClinicalTrials.gov
A Research Study of a New Medicine NNC0363-1063 in Healthy Participants and Participants With Type 1 Diabetes
Results posted· ClinicalTrials.gov
Use of a GLP-1R Agonist to Treat Opioid Use Disorder
FDA approval (supplemental)· FDA
Sponsor: NOVO. Class: Labeling.
FDA approval (supplemental)· FDA
Sponsor: NOVO NORDISK INC. Class: Labeling.
FDA approval (supplemental)· FDA
Sponsor: NOVO. Class: Labeling.
Primary completion· ClinicalTrials.gov
Efficacy and Safety of Liraglutide in the Treatment of Obesity Combined With Metabolism Associated Fatty Liver Disease
Primary completion· ClinicalTrials.gov
Basal Plus GLP1-ra on Glycemic Variability in CKD
Trial started· ClinicalTrials.gov
Investigation of the Relationship Between Peripheral and Central Metabolic Changes Induced by GLP-1 Agonists
Results posted· ClinicalTrials.gov
Afrezza With Basal Combination (ABC): Afrezza® Combined With AID Pump or Insulin Degludec in Adults With Type 1 Diabetes
Primary completion· ClinicalTrials.gov
Liraglutide in the Prevention of Type 2 Diabetes After Gestational Diabetes
Results posted· ClinicalTrials.gov
Effect of GLP-1 Receptor Agonism After Sleeve Gastrectomy
Primary completion· ClinicalTrials.gov
A Research Study Looking at How the Use of NovoPen® 6 for Treatment With Tresiba® & Fiasp® Affects the Blood Sugar Level in Patients With Ty
Primary completion· ClinicalTrials.gov
Liraglutide Effects on Epicardial Fat Inflammatory Genes
Results posted· ClinicalTrials.gov
Gla-300 and IDeg-100 in Insulin-Naïve People With Type 2 Diabetes Mellitus and Renal Impairment
Trial started· ClinicalTrials.gov
A Trial Investigating the Efficacy and Safety of Insulin Degludec/Liraglutide Injection in Subjects With Type 2 Diabetes
Trial registered· ClinicalTrials.gov
A Trial Investigating the Efficacy and Safety of Insulin Degludec/Liraglutide Injection in Subjects With Type 2 Diabetes
Trial registered· ClinicalTrials.gov
A Clinical Study of GZR33 and GZR101 in Healthy Subjects
Primary completion· ClinicalTrials.gov
A Study of Insulin Degludec/Insulin Aspart Biosimilar (22011) Compared With Insulin Degludec/Insulin Aspart(Ryzodeg) in Participants With Ty
Trial registered· ClinicalTrials.gov
A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GZR4 in Subjects With Type 2 Diabetes
Results posted· ClinicalTrials.gov
Saxenda in Obesity Services (STRIVE Study)
Results posted· ClinicalTrials.gov
Transition From Basal/Bolus to Once-weekly Subcutaneous Semaglutide and Basal Insulin in Patients With T2D
Results posted· ClinicalTrials.gov
Efficacy of Liraglutide Therapy in Patients With IPAA
Results posted· ClinicalTrials.gov
EMI-EHP Weight Management and Type 2 Diabetes Pragmatic Trial
Results posted· ClinicalTrials.gov
Effect of Liraglutide on Neural Responses to High Fructose Corn Syrup in Individuals With Obesity.
Trial registered· ClinicalTrials.gov
Efficacy and Safety of Liraglutide in the Treatment of Obesity Combined With Metabolism Associated Fatty Liver Disease
Primary completion· ClinicalTrials.gov
Stem Cell Mobilization (Plerixafor) and Immunologic Reset in Type 1 Diabetes (T1DM)
Primary completion· ClinicalTrials.gov
A Trial Comparing the Efficacy and Safety of GZR4 Injection Versus Insulin Degludec in Subjects with Type 2 Diabetes Mellitus
Primary completion· ClinicalTrials.gov
Incretin-based Therapy in Preclinical Type 1 Diabetes in Adults
Primary completion· ClinicalTrials.gov
A Study to Investigate the Safety and Tolerability of LY3938577 in Healthy Participants and Participants With Type 2 Diabetes Mellitus
Primary completion· ClinicalTrials.gov
A Trial to Investigate the Single Dose Pharmacokinetics of Insulin Degludec/Liraglutide in Healthy Chinese Subjects
Trial registered· ClinicalTrials.gov
A Trial to Investigate the Single Dose Pharmacokinetics of Insulin Degludec/Liraglutide in Healthy Chinese Subjects
Trial registered· ClinicalTrials.gov
Phase 1 Study Assessing the Pharmacokinetics of NEX-22A in Subjects With T2D
Trial registered· ClinicalTrials.gov
LIROH - Liraglutide for Obesity in HIV
Trial started· ClinicalTrials.gov
Phase 1 Study Assessing the Pharmacokinetics of NEX-22A in Subjects With T2D
Primary completion· ClinicalTrials.gov
Insulin Degludec vs Insulin Glargine for Glycemic Control in Critical Illness Hyperglycemia
Results posted· ClinicalTrials.gov
A Study of Tirzepatide in Overweight and Very Overweight Participants
Trial started· ClinicalTrials.gov
A Study of LY3938577 in Healthy Participants and Participants With Type 1 Diabetes Mellitus (T1DM)
Primary completion· ClinicalTrials.gov
A Study of Insulin Efsitora Alfa (LY3209590) Compared With Insulin Degludec in Participants With Type 2 Diabetes Currently Treated With Basa
Primary completion· ClinicalTrials.gov
A Study of Insulin Efsitora Alfa (LY3209590) Compared With Insulin Degludec in Participants With Type 1 Diabetes Treated With Multiple Daily
Trial started· ClinicalTrials.gov
A Trial to Investigate the Single Dose Pharmacokinetics of Insulin Degludec/Liraglutide in Healthy Chinese Subjects
Trial started· ClinicalTrials.gov
LIROH - Liraglutide for Obesity in HIV
Trial registered· ClinicalTrials.gov
Liraglutide in Preventing Delirium in Diabetic Elderly After Cardiac Surgery
Primary completion· ClinicalTrials.gov
A Study of Insulin Efsitora Alfa (LY3209590) Compared to Degludec in Adults With Type 2 Diabetes Who Are Starting Basal Insulin for the Firs
Trial started· ClinicalTrials.gov
Study to Evaluate the Safety and Effectiveness of Saxenda® for Weight Management in Routine Clinical Practice in Taiwan.
Results posted· ClinicalTrials.gov
Saxenda® in Obese or Overweight Patients With Stable Bipolar Disorder (Investigator Initiated)
Primary completion· ClinicalTrials.gov
INHALE-3: Afrezza® Combined With Insulin Degludec Versus Usual Care in Adults With Type 1 Diabetes
Results posted· ClinicalTrials.gov
Research Study to Compare a New Medicine "Fast-acting Insulin Aspart" to Another Medicine "Insulin Aspart" in Chinese People With Diabetes
Primary completion· ClinicalTrials.gov
Liraglutide (Saxenda(R)) in Adolescents With Obesity After Sleeve Gastrectomy
Results posted· ClinicalTrials.gov
Safety and Efficacy of Liraglutide in Parkinson's Disease
Primary completion· ClinicalTrials.gov
A Study to Assess the Effects of CT-868 Treatment on Glucose Homeostasis in Participants with Type 1 Diabetes
Trial registered· ClinicalTrials.gov
A Study to Test How a New Long-acting Insulin Works in the Body of Patients With Type 2 Diabetes During Exercise and Prolonged Fasting
Results posted· ClinicalTrials.gov
Effects of Single Doses of Liraglutide and Dapagliflozin on Ketogenesis in Type 1 Diabetes
Trial registered· ClinicalTrials.gov
A Study of LY3938577 in Healthy Participants and Participants With Type 1 Diabetes Mellitus (T1DM)
Results posted· ClinicalTrials.gov
Comparison of Glargine to Degludec Insulin Transition With or Without a Bridging Glargine Dose
Trial registered· ClinicalTrials.gov
Study to Evaluate the Safety and Effectiveness of Saxenda® for Weight Management in Routine Clinical Practice in Taiwan.
Trial started· ClinicalTrials.gov
A Study to Test How a New Long-acting Insulin Works in the Body of Patients With Type 2 Diabetes During Exercise and Prolonged Fasting
Results posted· ClinicalTrials.gov
A Study Using Medical Records of Danish People With Type 2 Diabetes Comparing Empagliflozin and Glucagon-Like Peptide-1 Receptor Agonists (G
Primary completion· ClinicalTrials.gov
The Effect of GLP-1 Agonist in Patients With Hypothalamic Obesity: Prospective, Pilot Study
Trial started· ClinicalTrials.gov
Effect of Liraglutide in Obese Women With Polycystic Ovary Syndrome
Trial started· ClinicalTrials.gov
Study of Liraglutide (A Weight Loss Drug) in High Risk Obese Participants With Cognitive and Memory Issues
Results posted· ClinicalTrials.gov
Dapagliflozin As Additional Treatment To Liraglutide And Insulin In Patients With Type 1 Diabetes
Trial registered· ClinicalTrials.gov
The Effect of GLP-1 Agonist in Patients With Hypothalamic Obesity: Prospective, Pilot Study
Results posted· ClinicalTrials.gov
Liraglutide in Type 1 Diabetes
Trial registered· ClinicalTrials.gov
Liraglutide Effectiveness in Preoperative Weight-loss for Bariatric-metabolic Surgery
Trial registered· ClinicalTrials.gov
A Trial Comparing the Efficacy and Safety of GZR4 Injection Versus Insulin Degludec in Subjects with Type 2 Diabetes Mellitus
Primary completion· ClinicalTrials.gov
Obesity Treatment to Improve Diabetes
2023
Primary completion· ClinicalTrials.gov
Liraglutide in Acute Minor Ischemic Stroke or High-risk Transient Ischemic Attack Patients With Type 2 Diabetes Mellitus
Primary completion· ClinicalTrials.gov
Safety and Efficacy of Insulin Degludec/Insulin Aspart in Patients With T1DM
Trial registered· ClinicalTrials.gov
Insulin Degludec vs Insulin Glargine for Glycemic Control in Critical Illness Hyperglycemia
Trial registered· ClinicalTrials.gov
Study of Liraglutide (A Weight Loss Drug) in High Risk Obese Participants With Cognitive and Memory Issues
Trial registered· ClinicalTrials.gov
A Research Study in Saudi Arabia to Understand How the Dose Check App Used With Tresiba Treatment Helps to Control Blood Sugar Level
Trial started· ClinicalTrials.gov
Insulin Degludec vs Insulin Glargine for Glycemic Control in Critical Illness Hyperglycemia
Trial started· ClinicalTrials.gov
A Research Study in Saudi Arabia to Understand How the Dose Check App Used With Tresiba Treatment Helps to Control Blood Sugar Level
Trial started· ClinicalTrials.gov
A Study to Investigate the Safety and Tolerability of LY3938577 in Healthy Participants and Participants With Type 2 Diabetes Mellitus
Trial registered· ClinicalTrials.gov
A Study to Investigate the Safety and Tolerability of LY3938577 in Healthy Participants and Participants With Type 2 Diabetes Mellitus
Trial started· ClinicalTrials.gov
Efficacy and Safety of Liraglutide in the Treatment of Obesity Combined With Metabolism Associated Fatty Liver Disease
Primary completion· ClinicalTrials.gov
A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GZR4 in Subjects With Type 2 Diabetes
Trial started· ClinicalTrials.gov
Liraglutide and Metformin Combination on Weight Loss, Metabolic - Endocrine Parameters and Pregnancy Rate in Women With PCOS, Obesity and In
Primary completion· ClinicalTrials.gov
Incretin and Treatment With Inhibition of Sodium-glucose Cotransporter-2 Combination Insights Into Mechanisms Implicated in Congestive Heart
Trial registered· ClinicalTrials.gov
Harmonizing RCT-Duplicate Emulations In A Real World Replication Program (HARRP)
Primary completion· ClinicalTrials.gov
Efficacy of Liraglutide Therapy in Patients With IPAA
Primary completion· ClinicalTrials.gov
Effect of GLP-1 Receptor Agonism After Sleeve Gastrectomy
Primary completion· ClinicalTrials.gov
HbA1c Variability in Type II Diabetes
Results posted· ClinicalTrials.gov
Daily Liraglutide for Nicotine Dependence
Results posted· ClinicalTrials.gov
Multiple Ascending Dose Study of AMG 598 in Adults With Obesity
Primary completion· ClinicalTrials.gov
Use of a GLP-1R Agonist to Treat Opioid Use Disorder
Results posted· ClinicalTrials.gov
IDegLira HIGH Trial
Trial started· ClinicalTrials.gov
Research on Timing of Liraglutide Therapy in Patients With Obesity After Metabolic Surgery
Primary completion· ClinicalTrials.gov
Harmonizing RCT-Duplicate Emulations In A Real World Replication Program (HARRP)
Primary completion· ClinicalTrials.gov
Risk of Hypoglycemia in the Transition From Inpatient to Outpatient Setting. Comparative Study of Basal-bolus Insulin Versus Basal Insulin P
Trial started· ClinicalTrials.gov
A Trial Comparing the Efficacy and Safety of GZR4 Injection Versus Insulin Degludec in Subjects with Type 2 Diabetes Mellitus
Results posted· ClinicalTrials.gov
Title: Therapeutic Targets in African-American Youth With Type 2 Diabetes
Primary completion· ClinicalTrials.gov
SCALE KIDS: Research Study to Look at How Well a New Medicine is at Lowering Weight in Children With Obesity
Trial registered· ClinicalTrials.gov
Effect of Liraglutide in Obese Women With Polycystic Ovary Syndrome
Primary completion· ClinicalTrials.gov
Gla-300 and IDeg-100 in Insulin-Naïve People With Type 2 Diabetes Mellitus and Renal Impairment
Trial registered· ClinicalTrials.gov
Liraglutide and Metformin Combination on Weight Loss, Metabolic - Endocrine Parameters and Pregnancy Rate in Women With PCOS, Obesity and In
Results posted· ClinicalTrials.gov
Research Study Investigating How Well NNC0174-0833 Works in People Suffering From Overweight or Obesity.
Results posted· ClinicalTrials.gov
Individualized Obesity Pharmacotherapy
Sources
FDA approvals, label revisions, and recalls come from the public openFDA APIs (Drugs@FDA, Drug Label, Drug Enforcement). Drug-safety communications come from the FDA RSS feed. Trial milestones come from ClinicalTrials.gov via the AACT pg dump. Pivotal-publication events come from PubMed, filtered to high-impact journals linked to a Phase 3 trial in our inventory.